For The Better

Passive income is particularly welcome during tough market times.

Passive income is particularly welcome during tough market times.

Lilly’s FDA rejection puts Biogen and its partner Eisai in the driver’s seat in the Alzheimer’s disease drug market.

Lilly’s FDA rejection puts Biogen and its partner Eisai in the driver’s seat in the Alzheimer’s disease drug market.

This health insurer appears poised to outperform the S&P 500 index for the third consecutive year in 2023.

This health insurer appears poised to outperform the S&P 500 index for the third consecutive year in 2023.

J&J’s future prospects look brighter than its year-to-date stock performance might imply.

J&J’s future prospects look brighter than its year-to-date stock performance might imply.

Among the three big wireless companies, one stands out as a great stock to own.

Among the three big wireless companies, one stands out as a great stock to own.

Investors haven’t had reason to cheer, as the e-commerce giant has gone nowhere over the past three years.

Investors haven’t had reason to cheer, as the e-commerce giant has gone nowhere over the past three years.

These beaten-down stocks have the potential to deliver big wins for investors.

These beaten-down stocks have the potential to deliver big wins for investors.

Now is the time to reflect on what went wrong in 2022 to become a better investor going forward.

Now is the time to reflect on what went wrong in 2022 to become a better investor going forward.

The Tex-Mex fast-casual pioneer is showing no signs of slowing down.

The Tex-Mex fast-casual pioneer is showing no signs of slowing down.

Kinder Morgan continues to blend capital discipline with regimented growth.

Kinder Morgan continues to blend capital discipline with regimented growth.